Aurobindo Pharma's Subsidiary CuraTeQ Biologics Receives Marketing Authorisation for Bevgolva, its Bevacizumab Biosimilar Version, from UK’s MHRA

CuraTeQ Biologics s.r.o., a step-down subsidiary of Aurobindo Pharma Limited, has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Bevgolva, its bevacizumab biosimilar version. Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins. Bevacizumab is used in the treatment of multiple cancers including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell carcinoma, cervical cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer. CuraTeQ Biologics Private Limited, a subsidiary of Aurobindo Pharma Limited, is a global biopharmaceutical company headquartered in Hyderabad, India. It is focused on developing biosimilars for the treatment of various cancers and autoimmune diseases. The company has end-to-end capabilities in producing a full range of products from bulk drug substance to fill-finish and packaged drug products.